低剂量阿哌沙班联合抗Xa监测与维生素K拮抗剂在肾脏替代治疗患者中的结局比较
该回顾性服务评估比较了接受肾脏替代治疗的终末期肾病患者使用阿哌沙班2.5 mg每日两次或维生素K拮抗剂的出血与血栓结局。阿哌沙班组无大出血,VKA组有4例(7.3%),差异无统计学意义(p=0.102);血栓事件(均为卒中)分别为1例与3例,差异亦无统计学意义(p=0.070)。提示阿哌沙班可能作为VKA不适用者的二线选择。
要点
- 阿哌沙班2.5 mg每日两次在RRT患者中未增加大出血风险。
- 血栓事件率两组差异无统计学意义,仅1例卒中与房颤相关。
核心结论
- 在接受肾脏替代治疗的终末期肾病患者中,阿哌沙班2.5 mg每日两次与VKA的出血和血栓结局相似。
- 阿哌沙班可能作为VKA不适用者的二线治疗选择。
- 需进一步研究阿哌沙班5 mg方案的安全性。
研究设计与样本
- 回顾性服务评估,在三级抗凝门诊比较阿哌沙班2.5 mg每日两次或VKA治疗患者的出血和血栓结局。
主要发现
- 阿哌沙班组无大出血,VKA组有4例(7.3%),差异无统计学意义(χ2=2.667,p=0.102)。
- 大出血或临床相关非大出血(CRNMB)时间无差异(χ2=1.252,p=0.263)。
- 血栓事件(均为卒中)VKA组1例(1.1事件/100患者年),阿哌沙班组3例(7.1事件/100患者年),差异无统计学意义(χ2=3.291,p=0.070)。
- 仅1例卒中与房颤相关。
临床怎么用
- 对于RRT合并房颤或静脉血栓栓塞症患者,若VKA不适用,可考虑阿哌沙班2.5 mg每日两次作为二线选择。
- 使用阿哌沙班时可参考谷浓度抗Xa监测,但多数低于一般人群参考上限。
- 阿哌沙班5 mg方案的安全性尚不明确,需进一步研究。
局限性
- 非随机对照,可能存在选择偏倚。
- 未报告阿哌沙班5 mg方案的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end-stage renal disease (ESRD) receiving renal replacement therapy (RRT). AIM: To compare thrombotic and safety outcomes in patients receiving either vitamin K antagonists (VKAs) or apixaban 2.5 mg twice daily in the context of ESRD and RRT. METHOD: Retrospective service evaluation comparing bleeding and thrombotic outcomes in patients treated with apixaban 2.5 mg BD or VKA in a tertiary anticoagulation clinic. Trough anti-Xa levels of apixaban patients were reviewed. Clinical features and outcomes were reviewed using electronic patient records. RESULTS: Fifty-five VKA and 33 apixaban patients were included in the analysis. There were no major bleeds in the apixaban cohort compared with 4 (7.3%) in the VKA cohort (χ2 = 2.667, p = 0.102). No difference in time to major or clinically relevant non-major bleeding (CRNMB) was found (χ2 = 1.252, p = 0.263). Rates of thrombotic events (all stroke) were 1 vs. 3 (1.1 and 7.1 events/100 patient-years) for VKA and apixaban, respectively (χ2 = 3.291, p = 0.070). Only one stroke was related to AF. Eighty-four of 85 trough anti-Xa levels analysed were below the upper limit of normal of the reference range for the general population. DISCUSSION: Our results suggest similar outcomes with VKA and apixaban in those receiving RRT, indicating apixaban may be a viable second-line treatment option in those for whom VKA may not be appropriate. Further investigation into the safety of the apixaban 5-mg regimen is warranted.
引用
- Bartoli-Abdou JK, Cohen AT, Vernon L, et al. Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy. Br J Clin Pharmacol. 2026. PMID: 42693888. doi:10.1002/bcp.70805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。